about
Cytokine Regulation of Microenvironmental Cells in Myeloproliferative NeoplasmsKIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on MastocytosisPAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesisThe PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophilsTarget interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growthDNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodelingCardiac glycosides induce cell death in human cells by inhibiting general protein synthesis.Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens.Azithromycin suppresses CD4(+) T-cell activation by direct modulation of mTOR activity.Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemiaIdentification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis.The Microtubule-Associated Protein Tau and Its Relevance for Pancreatic Beta Cells.Frequent occurrence of T cell-mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments.Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML.Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage.The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease.CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillanceLipoprotein(a) is not related to markers of insulin resistance in pregnancy.FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816HTransposon-mediated generation of BCR-ABL1-expressing transgenic cell lines for unbiased sensitivity testing of tyrosine kinase inhibitors.Hemeoxygenase-1 as a Novel Driver in Ritonavir-Induced Insulin Resistance in HIV-1-Infected Patients.Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia.Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.CD52 is a molecular target in advanced systemic mastocytosis.The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells.Oncostatin M is a FIP1L1/PDGFRA-dependent mediator of cytokine production in chronic eosinophilic leukemia.Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia.Identification of basophils as a major source of hepatocyte growth factor in chronic myeloid leukemia: a novel mechanism of BCR-ABL1-independent disease progression.Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.Prominin-1 (CD133, AC133) and dipeptidyl-peptidase IV (CD26) are indicators of infinitive growth in colon cancer cells.NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors.The tryptophan metabolite picolinic acid suppresses proliferation and metabolic activity of CD4+ T cells and inhibits c-Myc activation.Serum-tryptase at diagnosis: a novel biomarker improving prognostication in Ph(+) CML.Identification of oncostatin M as a STAT5-dependent mediator of bone marrow remodeling in KIT D816V-positive systemic mastocytosisDipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia.Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.Cooperation of ETV6/RUNX1 and BCL2 enhances immunoglobulin production and accelerates glomerulonephritis in transgenic mice.Endogenous erythroid colony formation in chronic myeloid leukemia: a recurrent finding associated with persistent minimal residual disease under imatinib.IL-4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells.
P50
Q26778929-84BFAE25-2458-4640-B609-8851635CC730Q26830207-25585785-DD17-4308-B99D-F83ED9AF1C89Q28302461-2BA684A2-9AA9-40D6-B169-507690B3FFE0Q28480417-9E39D793-282C-48E9-8063-95049B53974AQ28828739-04F95B6C-88FE-45C4-B278-5D903DC45782Q30355347-F93A9140-6C6B-4FF4-9F85-51890B44556EQ33519074-548B0FF3-5563-4C13-9402-4349FB2FDC1EQ34293285-B5DB8AAD-50FB-4636-B80A-12997062B1B5Q34675784-3759826A-EDE3-4E0B-B5BF-9F708339CF35Q35550174-549A775B-26CA-4259-84E8-05CAC54E10AAQ36406996-F4EC5B8F-EC74-4C59-A908-5013B3ED95B8Q36448430-9567D926-75F2-4A9A-BC68-BB79414F05EAQ36565528-2D4E1BB0-6FB6-4B5B-B1DF-F611B5859A1AQ36755221-22FFF0A4-674E-4085-9FE6-9A2211042E5BQ36977300-170EAE07-6EBA-4D3B-9599-6D4B078338D4Q36977305-D27CE32A-978D-4CF8-8233-5D110D235E8EQ37107530-87D89C6D-3443-4D8B-8FA0-E2B7A21578B0Q37362217-87745681-E7A7-47FD-A72B-9A638447C4EEQ37611613-AAE35C0D-07DD-4526-AF5F-9E72BED1470FQ38734590-621910BE-0D54-4FD3-8D70-EE704457DE93Q38734899-17D595ED-2819-4077-A690-DFF9EBB3EA42Q38866094-C8AABDBE-5FCF-4D7A-AB63-FAEE23639943Q38998107-D30952BC-7D20-4D4F-AA8E-8311C552B183Q39001575-29A9879D-89BE-402F-83C7-428084ABCAAFQ39093823-139444D0-9878-4C94-8303-F9553521FBDDQ39159911-E2228A36-0AC1-49A2-8846-B5EF66631A9DQ39241388-98C2E580-F085-41AF-86AF-FD45433039F3Q39294830-26F1D354-440F-4723-A31C-B2772857DA9CQ39448460-81726D06-7026-467A-BF69-A0E94E6449FEQ39523051-233A0A38-8DF5-4938-AC07-15C26EEEFF67Q39608346-86A702F8-0442-4E5C-8AB0-7AC91806A5D1Q40401088-479D7E7C-7C2F-4BF6-AE60-1FC2527A4169Q41189915-F2B79306-4955-44E4-AFC5-7938D8BFF45BQ41515301-B1264184-3D0E-42C4-BAA0-4E607E0F490CQ42045097-362DFCB2-39D9-4FEC-AE20-9C0355A151F7Q42217439-B29395CD-A3DC-426F-B4B3-2C373FA395DAQ42318090-CC17664C-BE90-4BA5-99CE-9D3975E9B3A7Q42594064-EA83F796-7527-4BDC-BA1D-5997311F9A9CQ47944231-BD6B1D55-24AA-464A-8775-C592CD5340E7Q48120081-965CF67F-09B9-474D-A462-664141EE8905
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Gregor Hoermann
@ast
Gregor Hoermann
@en
Gregor Hoermann
@es
Gregor Hoermann
@nl
Gregor Hoermann
@sl
type
label
Gregor Hoermann
@ast
Gregor Hoermann
@en
Gregor Hoermann
@es
Gregor Hoermann
@nl
Gregor Hoermann
@sl
prefLabel
Gregor Hoermann
@ast
Gregor Hoermann
@en
Gregor Hoermann
@es
Gregor Hoermann
@nl
Gregor Hoermann
@sl
P106
P1153
23987679200
P31
P496
0000-0002-7374-4380